Oculis Holding AG $OCS Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its holdings in Oculis Holding AG (NASDAQ:OCS) by 59.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 540,056 shares of the company’s stock after selling 805,672 shares during the quarter. Wellington Management Group LLP’s holdings in Oculis were worth $7,491,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. SR One Capital Management LP lifted its holdings in Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after buying an additional 318,522 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Oculis in the 4th quarter valued at about $9,862,000. Alyeska Investment Group L.P. raised its position in shares of Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares in the last quarter. Folketrygdfondet acquired a new stake in shares of Oculis during the 4th quarter worth about $3,651,000. Finally, Propel Bio Management LLC purchased a new stake in Oculis during the fourth quarter worth approximately $3,452,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Trading Down 0.1%

OCS opened at $12.16 on Wednesday. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis Holding AG has a 52 week low of $10.52 and a 52 week high of $34.47. The business’s 50 day moving average is $12.55 and its two-hundred day moving average is $19.93. The firm has a market cap of $705.04 million, a price-to-earnings ratio of -6.99 and a beta of 0.52.

Oculis (NASDAQ:OCS) last announced its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The business had revenue of $0.38 million for the quarter. On average, research analysts predict that Oculis Holding AG will post -2.01 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OCS. JPMorgan Chase & Co. lowered their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Oculis in a research report on Tuesday, August 25th. Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC dropped their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.